ARV-471: Robust Development Plans with Multiple Milestones CDK, cyclin-dependent kinase; SABCS, San Antonio Breast Cancer Symposium 2022+ 2H 2021 Complete Phase 1 dose escalation data (anticipated at SABCS) Initiate Phase 1b combination study with everolimus Begin Phase 2 study in early breast cancer (neoadjuvant setting) VERITAC Phase 2 data Phase 1b IBRANCE® (palbociclib) combination study data Phase 1b everolimus combination study data Ph 3 studies across multiple lines of therapy (+/- CDK4/6 inhibitor) Pivotal early BC program Umbrella study to explore multiple combination agents Exhibit 99.2

We are Progressing our Pipeline of Validated and “Undruggable” Targets in Oncology, Immuno-oncology, and Neuroscience †Denotes historically undruggable proteins Note: Pipeline is non-exhaustive and IND dates are anticipated. mCRPC, metastatic castration-resistant prostate cancer; ER+/HER2-, estrogen receptor+/human epidermal growth factor receptor 2-; NSCLC, non-small-cell lung carcinoma; CRC, colorectal cancer; FTLD-tau, frontotemporal lobar degeneration-tau; PSP, progressive supranuclear palsy; MSA, multiple systems atrophy ARVN Program Indication Exploratory Research IND Enabling Phase 1 Phase 2 Phase 3 Oncology / Immuno-oncology ARV-110 mCRPC ARV-766 mCRPC AR-V7† mCRPC ARV-471 ER+/HER2- Breast Cancer BCL6 B-cell Malignancies KRAS G12D/V† NSCLC, CRC, Pancreatic Undisclosed Solid Malignancies Myc† Solid Malignancies HPK1  Solid Malignancies Neuroscience Tau† FTLD-TAU, PSP, AD Alpha Synuclein  MSA, Parkinson’s mHTT Huntington’s Undisclosed Neurodegeneration  IND 2022 IND 2023 IND 2022 IND 2022 Global Partners with